# A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

> **NCT05108766** · PHASE3 · COMPLETED · sponsor: **Shenzhen Kangzhe Pharmaceutical Co., Ltd.** · enrollment: 220 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Tildrakizumab 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05108766
- **Lead sponsor:** Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2021-06-07
- **Final completion:** 2022-07-08
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05108766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05108766, "A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05108766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*